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Summary L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number
of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast
cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and
pathological responses in 44 patients with breast cancers >4 cm in diameter (46 tumours: T2, n = 6; T3,
n = 22; T4, n = 19), who received oral L-arginine 30 g day-' for 3 days prior to each cycle of CHOP
chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a
clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammo-
graphy revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients.
Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Further-
more, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and
,moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of
nutritional pharmacology in combination with existing treatment regimens.
Recently, chemotherapy has been used to reduce the size of
large, operable, breast cancers to enable conservative surgery
(instead of mastectomy) to be performed (Bonnadonna et al.,
1990; Smith et al., 1993). Clinical response rates of the
primary breast tumour to chemotherapy have ranged from
42% to 81% (Luboiniski et al., 1991; Rodger et al., 1992),
and complete pathological responses in up to 18% of cases
have been reported (Heys et al., 1993a). In an attempt to
improve these results, Swain et al. (1987) used a complex
regimen of chemo/endocrine therapy designed to synchronise
tumour cell DNA synthesis and thus enhance susceptibility to
chemotherapy. This approach resulted in a high clinical res-
ponse rate of 93%.
Recent interest has focused on the modulation of cell cycle
kinetics by specific nutrients. Animal studies have shown that
exogenous nutrients can stimulate tumour growth (Torosian
et al., 1983, 1984). In a rat mammary tumour, pulsed total
parenteral nutrition was shown to increase the number of
tumour cells in the S-phase and decrease the number in the
GO/GI and G2/M, phases (Torosian et al., 1984). Remvikos et
al. (1989) have shown that in patients with breast cancer
treated with primary chemotherapy the clinical response is
dependent on the number of tumour cells in the S-phase of
the cell cycle. These studies suggest that modulation of cell
cycle kinetics in man may enhance the response to cell cycle-
specific chemotherapeutic agents.
The amino acid L-arginine, given orally in high doses for 3
days to patients with breast cancer, has been shown to
stimulate tumour metabolic activity, as assessed by measur-
ing tumour protein synthesis in vivo. Furthermore, this in-
crease in protein synthesis correlated with an increased ex-
pression of the nuclear activation antigen, Ki67, which is
expressed by cells in the growth phase of the cell cycle (Park
et al., 1992). We have, for the first time in man, used a
specific dietary nutrient, L-arginine, to 'prime' tumour cells to
chemotherapy. The aim of this phase II study was to evaluate
the feasibility of using dietary supplementation with L-arginine,
in combination with primary chemotherapy, in the manage-
ment of patients with large (>4cm) breast tumours.
Patients and methods
Patients
Forty-four patients under 75 years of age with primary breast
cancers >4 cm diameter were evaluated. The diagnosis was
confirmed by fine-needle aspiration cytology or biopsy. All
patients had mammography and breast ultrasound, isotope
bone scan and abdominal ultrasound. The study was app-
roved by the Ethical Committee of Grampian Health Board
and Aberdeen University.
Study protocol
Patients received L-arginine prior to each cycle of
chemotherapy. If the residual tumour after four cycles was
greater than 4 cm in diameter, a further two cycles were
given and then patients proceeded to radiotherapy and then
surgery.
L-Arginine and chemotherapy Patients received a standard
diet supplemented with L-arginine 30 g day-' in three divided
doses for 3 days prior to each chemotherpy cycle.
Chemotherapy (CHOP) comprised vincristine 1.5 mg m-2
(maximum dose per cycle 2 mg), cyclophosphamide 1 g m-2
(maximum dose per cycle 1.5 g), doxorubicin 50 mg m-2
(maximum dose per cycle 90 mg), all given by intravenous
bolus injection, followed by prednisolone 40 mg orally for 5
days. Cycles were repeated at 21 day intervals if the white
cell count (WCC) was more than 3,000 x 1091-' and/or the
platelets were more than 150,000 x 109 I-'. If the WCC was
between 2,500 and 3,000 x 109 1` and platelets were less than
75,000 x 109I`, treatment was delayed for 1 week and
subsequent doses of doxorubicin and cyclophosphamide
reduced by 30%.
Radiotherapy Following chemotherapy, radiotherapy was
given as 20 daily fractions (5,000 cGy to the breast and
4,500 cGy to the lymph-draining areas). One patient with
bilateral breast cancer did not receive radiotherapy. All
patients received tamoxifen, 20 mg day-', commenced on
completion of radiotherapy.
Surgery This was performed 6 weeks after completion of
radiotherapy. Mastectomy was performed in patients with (i)
a residual tumour greater than 3 cm in diameter, (ii) a large
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pretreatment tumour/breast ratio or (iii) a patient preference
for mastectomy. All others underwent quadrantectomy. Sur-
gical treatment of the axilla was left to the discretion of the
surgeon, with axillary sampling being performed in 25
patients.
Assessment ofpatients during study
Prior to each cycle of chemotherapy, clinical measurements
of the tumour were made with calibrated skin callipers - four
diameters at 450 intervals (Cheung & Johnston, 1991). Mam-
mography and breast ultrasound were performed 3 weeks
after completion of chemotherapy and 6 weeks after com-
pletion of radiotherapy. Clinical and mammographic res-
ponses were classified using standard UICC criteria as pro-
gression of disease (PD), stable disease (SD), partial response
(PR) and complete response (CR) (Miller et al., 1981). Ult-
rasound responses were documented by measuring reductions
in tumour volume, using mean diameters and assuming the
tumour to be a sphere. A partial response on ultrasound was
defined as a reduction in volume of more than 65%.
Pathology
Histological responses of the tumour were assessed using a
modified version of the protocol described by Shimosato et
al. (1971):
Type I Changes in tumour cells but tumour nests not
destroyed
Type II Tumour structure destroyed to a mild degree
Type III Tumour structure destroyed to a moderate
Type IV
Type V
degree
Tumour structure destroyed to a severe
degree
No tumour cells in any of the specimens.
Results
The patients were aged 31-73 years (median 53 years); 19
were premenopausal and 25 post-menopausal. One patient
with schizophrenia withdrew from the study, leaving 44
patients with 46 tumours: one had a tumour on each breast
and one had two tumours in the same breast (Table I). All
T2 tumours were greater than 4 cm, as were four of the T4
tumours. Eight of the T4 tumours were greater than 10 cm in
diameter and the majority of tumours (28) were between 5
and 10cm in diameter. Six patients had inflammatory car-
cinomas (clinically) and four patients had bone metas-
tases.
Clinical responses
Following chemotherapy After four cycles of chemotherapy,
the overall response rate was 89%, with 22% (10/46) of
tumours achieving a CR and 67% (31/46) a PR and in 11%
(5/46) of tumours disease stabilised (95% confidence interval
for response rate 81-97%). The addition of two further
cycles of chemotherapy to ten patients did not alter the
overall response rates achieved (92%). A partial or complete
clinical response was obtained after a median of two and
three cycles respectively.
Table I TNM stage of breast cancers
Nl N2 N3
T2 4 3
T3 17 2 2
T4 6 5 7
T, tumour size; N, nodal status.
Following radiotherapy Clinical responses were assessed in
the 42 patients (43 tumours) who underwent radiotherapy.
One patient with bilateral breast cancer did not receive
radiotherapy, and another patient had radiotherapy discon-
tinued after 10 days owing to ulceration of a skin tumour
nodule. There was an overall respon-se rate of 95%, 30%
(13/43) of tumours showing a CR and 65% (28/43) a PR,
and 2% (1/43) became stable (95% CI for response rate
89-100%). One tumour demonstrated progression of
disease.
Imaging responses
Mammography Mammography did not detect tumours in 2
of the 44 patients (46 tumours) in this study. Following
chemotherapy, 50% (22/44) of tumours stabilised, 41% (18/
44) showed a PR and 9% (4/44) a CR (95% CI for response
rate 35-65%). Six weeks following radiotherapy, responses
were assessed in 40 patients (41 tumours): 24% (10/41) of
tumours stabilised, 56% (23/41) showed a PR and 20%
(8/41) a CR (95% CI for response rate 63-89%).
Ultrasound Ultrasound was unable reliably to assess res-
ponses in ten patients: eight had diffuse tumours, one had
undergone initial diagnostic biopsy and in one patient the
appearances were those of a benign tumour. In the remaining
34 patients (36 tumours), the responses following
chemotherapy alone were: PD or SD in 28% of tumours
(10/36), a PR in 55% (20/36) and a CR in 17% (6/36) (95%
CI for response rate 74-100%). In the 31 patients (32
tumours) who were assessed again 6 weeks following
radiotherapy, 19% of tumours (6/32) had progressed or
stabilised, 56% (18/32) showed a PR and 25% (8) a CR
(95% CI for response rate 67-95%)
Pathological responses
Following chemoradiotherapy all patients, except one who
had progressive disease, underwent surgery. Forty-five
tumours have been excised (28 mastectomies and 16 quad-
rantectomies). The maximum tumour diameters were com-
pared with the maximum diameters measured by clinical
examination, mammography and ultrasound 6 weeks post
radiotherapy (i.e. before surgery). The correlation coefficients
for clinical examination, ultrasonography and mammography
were 0.86, 0.70 and 0.74 respectively.
There were 44 invasive ductal carcinomas and one
mucinous carcinoma. Despite the presence of residual mac-
roscopic lesions in 30 of the specimens, this often consisted
predominantly of dense stromal tissue with variable destruc-
tion of tumour cell nests. Histological assessment of the
degree of tumour cell destruction revealed: type I, n = 1; type
II, n = 7; type III, n = 13; type IV, n = 16; and type V, n = 8.
Of the 25 patients in whom pathological nodal status was
available (median 4.5 nodes), there was residual nodal
involvement in 14. Although patients with a poorer
pathological response were more likely to have nodal
involvement, the pathological response in the breast did not
always correlate with the pathological nodal status.
Toxicity
Toxicity with this chemotherapeutic regimen was similar to
that previously documented (Delena et al., 1978; Grohn et
al., 1984). The only symptom that could be directly attri-
buted to L-arginine was a mild and self-limiting diarrhoea.
Nine patients experienced a 1 week delay in receiving
chemotherapy (low haemoglobin, 2; low WCC, 3; infection,
4). Three patients required a 30% reduction in their dose of
chemotherapy because of low WCC.
Surgical complications
Four patients who underwent quadrantectomy subsequently
developed cellulitis, three of whom subsequently underwent920 J. BRITTENDEN et al.
mastectomy because of poor wound healing (no residual
tumour found). Twelve patients who underwent mastectomy
had seromas and five developed cellulitis.
Long-termfollow-up
The median follow up of patients in this pilot study is 16.5
months (range 8-25 months). There have been three local
recurrences and six patients have died from metastatic
disease. The cumulative metastatic and survival probabilities
are 0.75 and 0.85 respectively.
Discussion
The clinical response rates obtained following L-arginine and
CHOP chemotherapy in this pilot study are higher than
those documented both in our previously reported patients
treated with the same chemotherapeutic regimen (Heys et al.,
1993b) and by other groups using similar chemotherapy
(Rodger et al., 1992). Dietary supplementation with L-
arginine was well tolerated and did not appear to potentiate
the side-effects of chemotherapy.
The response rates obtained in our study are similar to
those obtained by Sorace et al. (1985) and Swain et al. (1987)
and are amongst the highest documented. Lippman's
regimen, however, although designed to alter cell cycle
kinetics, involved a complicated chemotherapeutic/endocrine
protocol (doxorubicin, cyclophosphamide, methotrexate,
fluorouracil, tamoxifen and premarin), with a high rate of
non-compliance and morbidity. The median time to a partial
and complete response was four and five cycles respectively.
In our pilot study, a partial or complete response was
obtained after a median of two and three cycles respec-
tively.
As our study has shown, there are difficulties involved in
interpreting tumour responses. Previous studies comparing
clinical, mammographic or ultrasound assessment with max-
imal histological diameter of the tumour have demonstrated
no difference between the modalities (Pain et al., 1992),
although others have shown ultrasound to be better (Fornage
et al., 1987; Forouhi et al., 1992). In our study, ultrasound
and mammography gave substantially lower response rates
than did clinical examination. However, clinical examination
was found to correlate more closely with the size of the
residual macroscopic lesion (examined after surgical removal)
than imaging modalities. However, ultrasound appeared to
be more reliable than mammography in evaluating tumour
responses, except in those patients with very diffuse tumours,
in whom ultrasound was inferior.
The presence of a macroscopic lesion, determined either
clinically or by imaging techniques, does not necessarily
document accurately the extent of residual tumour.
Pathological assessment is important because patients with
either a complete clinical or pathological response and no
residual macroscopic disease, or marked tumour cell
degeneration, have improved survivals (Feldman et al., 1986;
Luboinski et al., 1991; Heys et al., 1993b). The complete
pathological response rate of 18% in our study occurred
following chemotherapy and radiotherapy, but no com-
parable published data are available. However, a complete
pathological response rate of 17% has been obtained in
operable tumours following similar chemotherapy (Anderson
et al., 1991). In their study, primary systemic therapy was
used on a selective basis for patients with operable breast
cancer of 4 cm or greater in diameter, i.e. chemotherapy was
reserved for patients with ER-negative tumours or those in
whom endocrine therapy had failed.
The length of follow-up of patients in the current study is
insufficient to determine if L-arginine is increasing the
disease-free interval or overall survival. Nevertheless, it has
been stated that 'pilot studies of potentially more effective
approaches to primary chemotherapy need to be pursued'
(Rubens, 1992). Our investigation has demonstrated the
feasibility of using selective nutrients, albeit in large amounts,
in conjunction with chemotherapy. L-arginine is a normal
nutrient, and it is cheap, readily available and well tolerated
by patients. The high response rates obtained in this pilot
study justify further evaluation of L-arginine in a randomised
double-blind study.
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